Shares of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW – Get Free Report) shot up 6.7% during mid-day trading on Tuesday . The company traded as high as $0.16 and last traded at $0.16. 19,060 shares changed hands during mid-day trading, a decline of 14% from the average session volume of 22,064 shares. The stock had previously closed at $0.15.
eFFECTOR Therapeutics Price Performance
The stock’s 50-day simple moving average is $0.13 and its 200-day simple moving average is $0.13.
eFFECTOR Therapeutics Company Profile
eFFECTOR Therapeutics, Inc, a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.
Further Reading
- Five stocks we like better than eFFECTOR Therapeutics
- What is Put Option Volume?
- Low Interest Rates Can Help These Commercial Banks Rally Higher
- Retail Stocks Investing, Explained
- Tesla Stock Drops on Weak Delivery Numbers and it May Fall More
- What Is WallStreetBets and What Stocks Are They Targeting?
- PVH Stock Gets 25% Discount: Is Now the Time to Buy?
Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
